JP2013526525A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526525A5
JP2013526525A5 JP2013510219A JP2013510219A JP2013526525A5 JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5 JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5
Authority
JP
Japan
Prior art keywords
day
pharmaceutical composition
composition according
isoindol
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526525A (ja
Filing date
Publication date
Priority claimed from US12/777,765 external-priority patent/US8404716B2/en
Application filed filed Critical
Publication of JP2013526525A publication Critical patent/JP2013526525A/ja
Publication of JP2013526525A5 publication Critical patent/JP2013526525A5/ja
Pending legal-status Critical Current

Links

JP2013510219A 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 Pending JP2013526525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/777,765 2010-05-11
US12/777,765 US8404716B2 (en) 2002-10-15 2010-05-11 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
PCT/US2011/035822 WO2011143147A1 (en) 2010-05-11 2011-05-10 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine

Publications (2)

Publication Number Publication Date
JP2013526525A JP2013526525A (ja) 2013-06-24
JP2013526525A5 true JP2013526525A5 (OSRAM) 2014-04-17

Family

ID=44314968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510219A Pending JP2013526525A (ja) 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Country Status (6)

Country Link
US (4) US8404716B2 (OSRAM)
EP (2) EP3219317A1 (OSRAM)
JP (1) JP2013526525A (OSRAM)
CN (1) CN103025330A (OSRAM)
AU (1) AU2011253161B2 (OSRAM)
WO (1) WO2011143147A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
CN104039330A (zh) * 2011-09-26 2014-09-10 细胞基因公司 化疗耐药性的癌症的联合治疗
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
LT3182996T (lt) 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US20190117787A1 (en) * 2016-04-15 2019-04-25 Seattle Genetics, Inc. Combinations of cd33 antibody drug conjugates with hypomethylating agents
EP3463463A4 (en) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
IL262565B (en) 2016-06-06 2022-08-01 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
JP7246309B2 (ja) 2016-12-08 2023-03-27 リクスト・バイオテクノロジー，インコーポレイテッド 免疫応答を調節するためのオキサビシクロヘプタン
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CA3211506A1 (en) 2018-02-07 2019-08-15 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
JP7541974B2 (ja) * 2018-08-26 2024-08-29 カーディフ・オンコロジー・インコーポレイテッド Ｐｌｋ１標的のリン酸化状態及びｐｌｋ１阻害剤を用いた癌の治療
EP3846800A4 (en) 2018-09-04 2022-08-24 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CA3121188A1 (en) * 2018-11-30 2020-06-04 Mei Pharma, Inc. Combination therapies for high and very high risk mds
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP4470618A3 (en) 2019-03-06 2025-03-05 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN109771643A (zh) * 2019-03-06 2019-05-21 厦门大学附属中山医院 儿童地中海贫血干细胞移植预处理联合化疗剂
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
KR20220003552A (ko) * 2019-04-22 2022-01-10 스타트온 테라퓨틱스, 인크. 레날리도미드 및 다른 면역조정제의 연속적 전달
WO2021080935A1 (en) * 2019-10-21 2021-04-29 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
AU2020372333A1 (en) * 2019-10-21 2022-04-28 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
BR112022008652A2 (pt) * 2019-11-05 2022-07-19 Hoffmann La Roche Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
CA3204385A1 (en) 2021-01-08 2022-07-14 Rod L. Hartwig Stable solutions of immunomodulatory imide compounds for parenteral use
WO2025024484A1 (en) * 2023-07-25 2025-01-30 Duke University Compositions and methods for treating blood cancer

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228601A (en) 1964-02-20 1966-01-11 Monarch Marking Systems Inc Controls for marking machine
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0505552A4 (en) 1990-10-12 1994-06-08 Amgen Inc Megakaryocyte maturation factors
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5641758A (en) * 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6432924B1 (en) * 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
MX9702723A (es) 1994-10-28 1998-04-30 Advanced Health Med E Systems Sistema de administracion de recetas.
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
PL195916B1 (pl) 1996-07-24 2007-11-30 Celgene Corp Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
AU729247B2 (en) * 1996-08-12 2001-01-25 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU8909898A (en) 1997-08-22 1999-03-16 Deka Products Limited Partnership Health care system and method for physician order entry
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
JP4695259B2 (ja) * 1998-03-16 2011-06-08 セルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
AU771015B2 (en) * 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6890547B1 (en) * 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
ATE340563T1 (de) * 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US20020022627A1 (en) * 2000-03-31 2002-02-21 Dannenberg Andrew J. Inhibition of cyclooxygenase-2activity
JP4679028B2 (ja) 2000-05-15 2011-04-27 セルジーン コーポレイション 結腸直腸癌を治療するための組成物および方法
DE60118571T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
AU2001280161A1 (en) 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
ES2338534T3 (es) * 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
US20030220254A1 (en) * 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
CA2752140A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2004319759A1 (en) 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
KR101164696B1 (ko) 2004-04-14 2012-07-11 셀진 코포레이션 골수이형성 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 상기 화합물을 포함하는 조성물
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008027049A1 (en) 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20100311683A1 (en) 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US8846628B2 (en) * 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
DK2391355T3 (en) 2009-05-19 2017-02-27 Celgene Corp FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Similar Documents

Publication Publication Date Title
JP2013526525A5 (OSRAM)
JP2009545600A5 (OSRAM)
JP2007045839A5 (OSRAM)
Rothenberg Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond
TWI782906B (zh) 惡性腫瘤治療用製劑及組合物
EP3194368B1 (en) Benzo-heterocyclic compounds and their applications
JP2014065696A5 (OSRAM)
JP2014148535A5 (OSRAM)
JP2014040437A5 (OSRAM)
JP2006507271A5 (OSRAM)
JP2005530784A5 (OSRAM)
JP2014532704A5 (OSRAM)
JP2012180381A5 (OSRAM)
JP2009510171A5 (OSRAM)
JP2013526525A (ja) レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法
JP2017524031A5 (OSRAM)
JP2010520289A5 (OSRAM)
CN103596935A (zh) Cxcr4拮抗剂的用途
IL168061A (en) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)- piperidine- 2, 6-dione for use in a medicament for treating and managing myelodysplastic syndromes
JP2011500805A5 (OSRAM)
JP6898329B2 (ja) 併用療法
JP2009539994A5 (OSRAM)
JP2010528091A5 (OSRAM)
CN111870600B (zh) 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用
CN101610776A (zh) 包含CNDAC(2′-氰基-2′-脱氧-N4 -棕榈酰基-1-β-D-阿拉伯呋喃糖基-胞嘧啶)和细胞毒剂的组合